J&J Suggests Targeting OTC Monograph With Public-Private Initiative
This article was originally published in The Tan Sheet
Executive Summary
An FDA guidance provides the framework for J&J consumer business executives’ suggestions to improve the OTC drug review. A public-private partnership “is key to developing and delivering a comprehensive solution,” says Lynne Szczepaniak, regulatory affairs VP at J&J’s McNeil Consumer Healthcare subsidiary.
You may also be interested in...
Flow Restrictors Limit Children’s Access To Drugs; Standards Needed
Only 6% of children emptied medicine bottles with flow restrictors in 10 minutes, compared to 82% who emptied bottles with incompletely closed child-resistant caps within two minutes, a CDC study shows. But researchers and stakeholders suggest waiting for industry standards to implement flow restrictors.
Sentinel Will Benefit From Administration's Health IT Push
The Obama administration's emphasis on wiring health care comes at a key time for FDA's Sentinel postmarketing medical product safety monitoring project, according to Commissioner Margaret Hamburg
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.